Kinase modulation and indications therefor

A method for treating a subject suffering from or at risk of a Flt3 mediated disease or condition, said method comprising administering to the subject an effective amount of a compound having the chemical structure of Formula III,

• or a salt, prodrug, tautomer or isomer thereof,
• wherein:
• L4 is —CH2—, —CH2CH2—, —CH(R40)—, —C(O)— or —C(O)NH—;
• R81 is selected from the group consisting of hydrogen, —OR41, —CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, —NHR41, —NR41R41, —OR41 and —S(O)2R41;
• R82 is selected from the group consisting of hydrogen, C1-3 alkyl, fluoro substituted C2-3 alkyl, OH, C1-3alkoxy, and fluoro substituted C1-3 alkoxy;
• R83 is heterocycloalkyl, heteroaryl, or
• in which
• indicates the attachment point of R83 to L4 of Formula III, wherein heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl,
• cycloalkylamino, —NHR41, —NR41R41, —OR41 and —S(O)2R41;
• R92, R93, R94, R95, and R96 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl,
• cycloalkylamino, —NHS(O)2R41, —NHC(O)R41, —NHR41, —NR41R41, —OR41 and —S(O)2R41;
• R49 is selected from the group consisting of lower alkyl, and fluoro substituted lower alkyl;
• R41 at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R41 or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of —OH, —NH2, —CN, —NO2, —S(O)2NH2, —OR41, —SR42, —NHR42, —NR42R42;
• —NR39C(O)R42, —NR39S(O)2R42, —S(O)2R42, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
• and
• R42 at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, —CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy.